CDK9 and pancreatic neoplasm: Indeed, it has been shown that CDK9 inhibition decreases the expression of short-lived anti-apoptotic factors cFLIP, cIAP1/2 and MCL-1 in a variety of tumour entities, including NSCLC, pancreatic cancer, colorectal cancer, and melanoma [23, 24].